Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01303341CT.gov Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma | — | Active Not Recruiting | — | — | — |
NCT00565968CT.gov Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg | — | Completed | — | — | — |
NCT00811759CT.gov Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma | — | Unknown | — | — | — |
NCT00538005CT.gov Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma | — | Unknown | — | — | — |
NCT00492505CT.gov Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma | — | Unknown | — | — | — |
NCT00387751CT.gov Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma | — | Completed | — | — | — |
NCT00110019CT.gov Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT00602576CT.gov Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cutaneous Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sorafenib (this asset) | National Cancer Institute (NCI) | P3 | BB · 66 |
| Alpha-Interferon | MIPO Clinic | P3 | BBB |
| TIL | City of Hope Medical Center | P2 | BBB |
| Cis-Diamminedichloroplatinum Ii | MIPO Clinic | P3 | BBB |
| Dacarbazine | Linnaeus Therapeutics, Inc. | P3 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BBB |
| Nivestim | Vastra Gotaland Region | P3 | BB |
| Multi-Epitope Melanoma Peptide Vaccine | Craig L Slingluff, Jr | P2 | BB |
| Mart-1 Antigen | Mayo Clinic | P2 | BB |
+42 more in the Cutaneous Melanoma cohort
Other indications for Sorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P4 | BBB · 79 |
| Portal Vein Thrombosis | — | P4 | BBB · 74 |
| Adult Hepatocellular Carcinoma | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sorafenib in Cutaneous Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sorafenib-cutaneous-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →